• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ocular Therapeutix Inc. (Amendment)

    2/13/24 5:09:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCUL alert in real time by email
    SC 13G/A 1 tv01590-oculartherapeutixinc.htm SCHEDULE 13G/A oculartherapeutixinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 2)*

    Name of issuer:  Ocular Therapeutix Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  67576A100

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  67576A100

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    130,326

    7.  SOLE DISPOSITIVE POWER

    4,959,246

    8.  SHARED DISPOSITIVE POWER

    158,856

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,118,102

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    4.46%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Ocular Therapeutix Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    24 Crosby Drive
    Bedford, MA 01730

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    67576A100

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $OCUL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OCUL

    DatePrice TargetRatingAnalyst
    9/15/2025$21.00Buy
    Chardan Capital Markets
    4/8/2025Outperform
    William Blair
    3/18/2025$17.00Outperform
    RBC Capital Mkts
    3/11/2025$15.00Buy
    Needham
    10/16/2024Sector Outperform
    Scotiabank
    6/20/2024$7.00 → $11.00Hold → Buy
    TD Cowen
    5/31/2024$15.00Overweight
    Piper Sandler
    2/9/2024$15.00Buy
    BofA Securities
    More analyst ratings

    $OCUL
    SEC Filings

    View All

    Ocular Therapeutix Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    6/12/26 4:23:11 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Ocular Therapeutix Inc.

    10-Q - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    5/5/26 7:28:34 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - OCULAR THERAPEUTIX, INC (0001393434) (Filer)

    5/5/26 7:06:45 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dugel Pravin gifted 50,092 shares and received a gift of 50,092 shares, decreasing direct ownership by 2% to 2,547,078 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    6/18/26 4:01:15 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Warden Charles M was granted 14,000 shares, increasing direct ownership by 16% to 100,464 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    6/12/26 5:23:27 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Graves Adrienne L was granted 14,000 shares, increasing direct ownership by 28% to 64,000 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    6/12/26 5:22:42 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to eleven newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards were granted effective as of July 6, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 34,700 shares of Ocular’s com

    7/9/26 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

    BEDFORD, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in July 2026. Upcoming Scientific Conferences: 9th Annual OIS Retina Innovation Summit (OIS Retina 2026): July 14, 2026Montréal, Quebec Presentation: Ocular Therapeutix: Retina Experience RedefinedPresentation Date/Time: Tuesday, July 14, 2026, 11:37 – 11:44 AM EDTPresenter: Peter K. Kaiser, MD, Chief Development Officer Panel Title: The Impact of Recent FDA Guidance on Drug DevelopmentPanel Date/Time: Tuesday, July

    7/1/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    BEDFORD, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular" or the "Company")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Kelley Allison, the Company’s new SVP, Market Access and Health Policy. The awards were made as an inducement material to the recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards granted to Ms. Allison were effective as of June 15, 2026 and consist of a non-statutory stock option award to purchase up t

    6/22/26 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lindstrom Richard L Md bought $69,600 worth of shares (10,000 units at $6.96), increasing direct ownership by 6% to 172,704 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    5/12/25 8:50:46 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Summer Road Llc bought $7,000,000 worth of shares (930,851 units at $7.52) (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/27/24 4:43:51 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Ocular Therapeutix with a new price target

    Chardan Capital Markets initiated coverage of Ocular Therapeutix with a rating of Buy and set a new price target of $21.00

    9/15/25 8:09:22 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Ocular Therapeutix

    William Blair initiated coverage of Ocular Therapeutix with a rating of Outperform

    4/8/25 9:29:59 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Ocular Therapeutix with a new price target

    RBC Capital Mkts initiated coverage of Ocular Therapeutix with a rating of Outperform and set a new price target of $17.00

    3/18/25 7:53:57 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

    Enrollment underway in SOL-X long-term extension trial in wet AMD for subjects completing two-year follow-up in SOL-1 or SOL-R Announced positive Phase 3 SOL-1 results in February 2026, first ever successful wet AMD superiority trial comparing a novel investigative agent to an approved anti-VEGF SOL-1 Week 52 data presentations held at Macula Society and VBS meetings reinforce AXPAXLI's unmatched durability and sustained disease control data in wet AMD Commercial preparedness plans accelerated as Ocular intends to submit AXPAXLI NDA based on SOL-1 Week 52 data, subject to ongoing formal discussions with the U.S. FDA SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline read

    5/5/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

    BEDFORD, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, May 5, 2026 at 8:00 AM ET to discuss recent business progress and financial results for the first quarter ended March 31, 2026. Conference Call and Webcast Information: Date: Tuesday, May 5, 2026 at 8:00 AM ETParticipant Dial-In (U.S.): 1-800-343-4136Participant Dial-In (International): 1-203-518-9843Conference ID: OCULAR (required for entry)Webcast Access: Please click here The live and archived webcast can also be access

    4/28/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Leadership Updates

    Live Leadership Updates

    View All

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix® to Host Investor Day on June 13, 2024

    Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI™ in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of California, Irvine) and Dilsher S. Dhoot, MD (California Retina Consultants) In-person event with virtual access to take place on June 13, 2024, at 2:00 PM ET BEDFORD, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD

    6/5/24 7:30:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports First Quarter 2024 Results

    Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, Investor Day to Outline Updated Corporate Strategy BEDFORD, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degenerati

    5/7/24 4:05:00 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OCUL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ocular Therapeutix Inc.

    SC 13G - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 9:37:26 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/12/24 4:49:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care